Results of the RELATIVITY-098 clinical trial published in Nature Medicine show the presence of tumour is directly related to the effectiveness of combination immunotherapy for high risk and advanced melanoma, providing more evidence that neoadjuvant immunotherapy is the new frontier in treatment for melanoma, and other cancers.
MIA Medical Director, Professor Georgina Long AO, is leading the next group of clinical trials in the use of pre-surgery immunotherapy as life-saving treatment for melanoma. Results of one of these latest neoadjuvant immunotherapy clinical trials were today published in the prestigious Nature Medicine.
The International Neoadjuvant Melanoma Consortium (INMC), of which MIA’s Professor Long is a founder with three colleagues from MD Anderson USA, has been awarded the 2025 Society for Immunotherapy of Cancer Collaboration Award for its work in pioneering neoadjuvant immunotherapy for melanoma.
The pre-surgery use of combination immunotherapy as frontline treatment for high risk melanoma is now listed on the Pharmaceutical Benefits Scheme (PBS) and subsidised for all Australian patients.
Prestigious National Health and Medical Research Council (NHMRC) grants have been awarded for two clinical trials aiming to improve the accuracy of skin cancer diagnosis in Australia.
Three studies led by researchers at Melanoma Institute Australia (MIA) are paving the way for less surgical and drug intervention for early stage melanoma patients.
The NHMRC grant will enable MIA to lead an international clinical trial aiming to safely reduce surgery for high risk Stage III melanoma patients who have had a good response to neoadjuvant immunotherapy.
Skin checks are an important tool in the early detection of skin cancers. MIA & others in the skin cancer community have advocated for a more systematic, targeted & equitable approach to skin cancer screening in Australia. As a result, the Australian Gov't has allocated $10m for development of a Roadmap for a National Targeted Skin Cancer Screening Program.
We were delighted to have the honour of meeting with His Majesty King Charles III this week, a once-in-a-lifetime opportunity to shine an international spotlight on melanoma.
MIA’s leading experts and early career researchers have shared the world stage at the annual European Society for Medical Oncology (ESMO) Congress in Barcelona.
